Top of page

Healthcare & Life Sciences

Industry
From investors to startups to the world’s largest healthcare companies, clients turn to us on a full range of transactions and other legal matters.
Summary

Companies appreciate our depth of experience in areas including pharmaceuticals, biotechnology, and diagnostic and medical devices. Since 2010, we have completed approximately 575 capital markets transactions in healthcare, totaling over $470 billion. Over the same period, we advised on more than 200 M&A transactions, with a cumulative deal value of approximately $1.2 trillion and a market share of approximately 25%, according to data from Refinitiv.

Healthcare and life sciences clients trust in our understanding of the complex issues they face in acquisitions, divestitures, joint ventures, partnerships, strategic alliances, licensing arrangements, collaborations, distribution agreements, internal investigations and litigation.

Many transactions and other matters have an intellectual property component. Clients appreciate that our team includes lawyers with strong biomedical backgrounds such as Ph.D.s and biomedical engineering degrees.

Highlight

Data Item
$470+ billion
Highlight Quote
Aggregate value of capital markets transactions since 2010
Source
Refinitiv

Insights

Recognition

Recognition Cards
Title
Firm to Watch – Financial & Corporate
Recognition Source
LMG Life Sciences Awards, 2020
Title
Finance & Corporate Impact Deal of the Year
Award Detail
(Roche acquisition of Spark)
Recognition Source
LMG Life Sciences Awards, 2019
Title
High Yield Deal of the Year
Award Detail
(Valeant Pharmaceuticals refinancing)
Recognition Source
IFLR Americas Awards, 2018
Back to top